Associated Genetic Biomarkers
XRCC5 is altered in 0.98% of all cancers with colon adenocarcinoma, lung adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in XRCC5 are XRCC5 Mutation (0.15%), XRCC5 E287Kfs*11 (0.00%), XRCC5 E621K (0.00%), XRCC5 P446S (0.00%), and XRCC5 P711S (0.00%) .
XRCC5 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains XRCC5 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with XRCC5 status in the inclusion eligibility criteria most commonly target urothelial carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is XRCC5 Mutation .
Olaparib is the most frequent therapy in trials with XRCC5 as an inclusion criteria .
Significance of XRCC5 in Diseases
Urothelial Carcinoma +
XRCC5 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC5 status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.